Sacituzumab Govitecan-hziy + Pembrolizumab + Paclitaxel + nab-Paclitaxel + Gemcitabine + Carboplatin
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Triple Negative Breast Cancer
Conditions
Triple Negative Breast Cancer, PD-L1 Positive
Trial Timeline
Jul 25, 2022 → Feb 1, 2027
NCT ID
NCT05382286About Sacituzumab Govitecan-hziy + Pembrolizumab + Paclitaxel + nab-Paclitaxel + Gemcitabine + Carboplatin
Sacituzumab Govitecan-hziy + Pembrolizumab + Paclitaxel + nab-Paclitaxel + Gemcitabine + Carboplatin is a phase 3 stage product being developed by Merck for Triple Negative Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05382286. Target conditions include Triple Negative Breast Cancer, PD-L1 Positive.
What happened to similar drugs?
1 of 20 similar drugs in Triple Negative Breast Cancer were approved
Approved (1) Terminated (1) Active (18)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05382286 | Phase 3 | Active |
Competing Products
20 competing products in Triple Negative Breast Cancer